Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Molecular Cancer Therapeutics
|
May 28, 2021
Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models
Danlin Sun, Anna S Nikonova, Peishan Zhang, et al.
ACS Combinatorial Science
|
August 13, 2016
Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments
Sina Haftchenary, Shawn D Nelson, Laura Furst, et al.
Science (New York, N.Y.)
|
December 15, 2015
Polysialylation controls dendritic cell trafficking by regulating chemokine recognition
Eva Kiermaier, Christine Moussion, Christopher T Veldkamp, et al.
ACS Chemical Biology
|
May 26, 2016
Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo
Thomas B Sundberg, Yanke Liang, Huixian Wu, et al.
Scientific Reports
|
October 29, 2017
Behaviorally-determined sleep phenotypes are robustly associated with adaptive functioning in individuals with low functioning autism
Simonne Cohen, Ben D Fulcher, Shantha M W Rajaratnam, et al.
SLAS Discovery : Advancing Life Sciences R & D
|
March 29, 2021
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination
Ellen F Vieux, Roman V Agafonov, Lydia Emerson, et al.
Nature Chemical Biology
|
August 15, 2017
Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells
Liv Johannessen, Thomas B Sundberg, Daniel J O'Connell, et al.
Molecular Cancer Therapeutics
|
December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Jennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
Journal of Medicinal Chemistry
|
November 24, 2025
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
Katrina L Jackson, Ning Yin, Roman V Agafonov, et al.
Cancer Research
|
October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor Resistance
Bridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Molecular Cancer Therapeutics
|
May 28, 2021
Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models
Danlin Sun, Anna S Nikonova, Peishan Zhang, et al.
ACS Combinatorial Science
|
August 13, 2016
Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments
Sina Haftchenary, Shawn D Nelson, Laura Furst, et al.
Science (New York, N.Y.)
|
December 15, 2015
Polysialylation controls dendritic cell trafficking by regulating chemokine recognition
Eva Kiermaier, Christine Moussion, Christopher T Veldkamp, et al.
ACS Chemical Biology
|
May 26, 2016
Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo
Thomas B Sundberg, Yanke Liang, Huixian Wu, et al.
Scientific Reports
|
October 29, 2017
Behaviorally-determined sleep phenotypes are robustly associated with adaptive functioning in individuals with low functioning autism
Simonne Cohen, Ben D Fulcher, Shantha M W Rajaratnam, et al.
SLAS Discovery : Advancing Life Sciences R & D
|
March 29, 2021
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination
Ellen F Vieux, Roman V Agafonov, Lydia Emerson, et al.
Nature Chemical Biology
|
August 15, 2017
Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells
Liv Johannessen, Thomas B Sundberg, Daniel J O'Connell, et al.
Molecular Cancer Therapeutics
|
December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Jennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
Journal of Medicinal Chemistry
|
November 24, 2025
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
Katrina L Jackson, Ning Yin, Roman V Agafonov, et al.
Cancer Research
|
October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor Resistance
Bridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
Page
of 7